Decision Resources announced today the availability of a new report entitled Acute Exacerbations of Chronic Bronchitis, which finds the market for acute exacerbations of chronic bronchitis (AECB) drugs will see major competition. The report concludes that the introduction of ketolide drugs into the AECB market, rising antibiotics resistance levels, and generic competition, will all have major drug manufacturers fighting for space in this market.

  (Photo: )    Major Market Players 

Abbott, Aventis, Bayer and Bristol-Myers Squibb will all vie for stronger positioning within the AECB market -- a market that in 2001 totaled $1.1 billion in major pharmaceutical markets (the United States, the United Kingdom, France, Germany, Spain, Italy, and Japan).

"Aventis may have an edge with telithromycin (Ketek), the first to market in the new ketolide antibiotic drug class," says Margaret Jorgensen, analyst, Decision Resources. "However, Aventis and others will see major generic competition when patents expire on several key anti-infective agents in the near future."

About the Disease -- Acute Exacerbations of Chronic Bronchitis

Bronchitis is the inflammation of one or more bronchi. It is estimated that there were a total of 23 million diagnosed incident episodes of AECB in the seven major markets (United States, the United Kingdom, France, Germany, Spain, Italy, and Japan) in 2001, rising to 27 million diagnosed episodes in 2011. This growth, proceeding at an annual rate of 1.6% is largely the result of population growth -- particularly among the elderly population, the group most affected by the disease.

About Pharmacor

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Acute Exacerbations of Chronic Bronchitis is the latest Infectious Disease program from Pharmacor.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 25 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

AstraZeneca to Become Major Player in Lung Cancer Drug Market

View Now